- Home
- NAVI vs VRDN Comparison
NAVI vs VRDN Comparison
Compare NAVI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- VRDN
- Stock Information
- Founded
- NAVI 1973
- VRDN 2006
- Country
- NAVI United States
- VRDN United States
- Employees
- NAVI N/A
- VRDN N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- VRDN Medical Specialities
- Sector
- NAVI Finance
- VRDN Health Care
- Exchange
- NAVI Nasdaq
- VRDN Nasdaq
- Market Cap
- NAVI 1.4B
- VRDN 1.3B
- IPO Year
- NAVI N/A
- VRDN N/A
- Fundamental
- Price
- NAVI $15.57
- VRDN $15.89
- Analyst Decision
- NAVI Hold
- VRDN Strong Buy
- Analyst Count
- NAVI 7
- VRDN 11
- Target Price
- NAVI $13.64
- VRDN $38.50
- AVG Volume (30 Days)
- NAVI 764.5K
- VRDN 753.9K
- Earning Date
- NAVI 07-23-2025
- VRDN 08-07-2025
- Dividend Yield
- NAVI 4.11%
- VRDN N/A
- EPS Growth
- NAVI N/A
- VRDN N/A
- EPS
- NAVI 0.52
- VRDN N/A
- Revenue
- NAVI $699,000,000.00
- VRDN $302,000.00
- Revenue This Year
- NAVI N/A
- VRDN N/A
- Revenue Next Year
- NAVI $2.85
- VRDN $17,102.33
- P/E Ratio
- NAVI $30.04
- VRDN N/A
- Revenue Growth
- NAVI N/A
- VRDN 4.86
- 52 Week Low
- NAVI $10.53
- VRDN $9.90
- 52 Week High
- NAVI $16.97
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- NAVI 76.04
- VRDN 63.70
- Support Level
- NAVI $13.25
- VRDN $13.84
- Resistance Level
- NAVI $14.44
- VRDN $14.85
- Average True Range (ATR)
- NAVI 0.41
- VRDN 0.82
- MACD
- NAVI 0.15
- VRDN 0.03
- Stochastic Oscillator
- NAVI 91.82
- VRDN 91.93
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).